Moreover, while imatinib had no effect in mice with B-ALL induced by T315I BCR-ABL, treatment with the dual Src/ABL inhibitor dasatinib (which is also ineffective against the T315I BCR-ABL mutant) significantly prolonged survival. Here, ABL1 is linked to acute lymphoblastic leukemia.